Annotation Detail
Information
- Associated Genes
- PALB2
- Associated Variants
-
PALB2 BIALLELIC INACTIVATION
PALB2 BIALLELIC INACTIVATION - Associated Disease
- prostate cancer
- Source Database
- CIViC Evidence
- Description
- From 14 prostate cancer patients (88%) who had a response to olaparib, 7 patients had BRCA2 loss (4 with biallelic somatic loss, and 3 with germline mutations), 4 of 5 with had ATM aberrations and one had a biallelic inactivation of PALB2 (frameshift mutation and deletion).
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/1963
- Gene URL
- https://civic.genome.wustl.edu/links/genes/15013
- Variant URL
- https://civic.genome.wustl.edu/links/variants/532
- Rating
- 3
- Evidence Type
- Predictive
- Disease
- Prostate Cancer
- Evidence Direction
- Supports
- Drug
- Olaparib
- Evidence Level
- C
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 26510020
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Olaparib | Sensitivity | true |